Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Oscier

Showing results (81-90 of 98) with videos related to

Pageof 10
Sort By:
Blood|January 4, 2019
Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impactPanagiotis Baliakas, Sabine Jeromin, Michalis Iskas, et al.
Haematologica|December 23, 2017
No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets #1 and #2 treated with chemo(immuno)therapyPanagiotis Baliakas, Mattias Mattsson, Anastasia Hadzidimitriou, et al.
Nature Genetics|January 12, 2010
Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia riskDalemari Crowther-Swanepoel, Peter Broderick, Maria Chiara Di Bernardo, et al.
The Journal of Pathology|November 29, 2018
Disease-biased and shared characteristics of the immunoglobulin gene repertoires in marginal zone B cell lymphoproliferationsAliki Xochelli, Vasilis Bikos, Eleftheria Polychronidou, et al.
The Lancet. Haematology|April 1, 2016
Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre studyPanagiotis Baliakas, Anastasia Hadzidimitriou, Lesley-Ann Sutton, et al.
Blood|January 31, 2015
Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerationsPanagiotis Baliakas, Andreas Agathangelidis, Anastasia Hadzidimitriou, et al.
Nature Communications|April 8, 2015
Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasmsWilliam Tapper, Amy V Jones, Robert Kralovics, et al.
Leukemia|September 19, 2025
Clinical and transcriptomic characterization of patients with chronic lymphocytic leukemia harboring t(14;19): an ERIC studyAndrea Visentin, Enrico Gaffo, Moritz Fürstenau, et al.
Journal of Hematology & Oncology|July 21, 2025
Circular RNA signature of aggressive CLL with t(14;19)(q32;q13). An ERIC studyEleonora Roncaglia, Enrico Gaffo, Giulia Calabretto, et al.
Leukemia|April 24, 2025
ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarkerBirna Thorvaldsdottir, Larry Mansouri, Lesley-Ann Sutton, et al.
Pageof 10

Showing results (81-90 of 98) with videos related to

Sort By:
Pageof 10
Blood|January 4, 2019
Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impactPanagiotis Baliakas, Sabine Jeromin, Michalis Iskas, et al.
Haematologica|December 23, 2017
No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets #1 and #2 treated with chemo(immuno)therapyPanagiotis Baliakas, Mattias Mattsson, Anastasia Hadzidimitriou, et al.
Nature Genetics|January 12, 2010
Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia riskDalemari Crowther-Swanepoel, Peter Broderick, Maria Chiara Di Bernardo, et al.
The Journal of Pathology|November 29, 2018
Disease-biased and shared characteristics of the immunoglobulin gene repertoires in marginal zone B cell lymphoproliferationsAliki Xochelli, Vasilis Bikos, Eleftheria Polychronidou, et al.
The Lancet. Haematology|April 1, 2016
Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre studyPanagiotis Baliakas, Anastasia Hadzidimitriou, Lesley-Ann Sutton, et al.
Blood|January 31, 2015
Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerationsPanagiotis Baliakas, Andreas Agathangelidis, Anastasia Hadzidimitriou, et al.
Nature Communications|April 8, 2015
Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasmsWilliam Tapper, Amy V Jones, Robert Kralovics, et al.
Leukemia|September 19, 2025
Clinical and transcriptomic characterization of patients with chronic lymphocytic leukemia harboring t(14;19): an ERIC studyAndrea Visentin, Enrico Gaffo, Moritz Fürstenau, et al.
Journal of Hematology & Oncology|July 21, 2025
Circular RNA signature of aggressive CLL with t(14;19)(q32;q13). An ERIC studyEleonora Roncaglia, Enrico Gaffo, Giulia Calabretto, et al.
Leukemia|April 24, 2025
ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarkerBirna Thorvaldsdottir, Larry Mansouri, Lesley-Ann Sutton, et al.
Pageof 10